Aridis Pharmaceuticals Inc., a San Jose-based company focused on the discovery and development of targeted immunotherapies to treat life-threatening infections, launched an IPO of 2 million shares of its common stock that would raise $28 million at the midpoint of the company's proposed offering price range.